Nippon Life Global Investors Americas Inc. Grows Stake in Zoetis Inc. $ZTS

Key Points

• Nippon Life Global Investors Americas Inc. increased its holdings in Zoetis Inc. by 8.0%, acquiring an additional 2,880 shares, bringing their total to 38,740 shares valued at approximately $6.38 million.
• Zoetis recently reported a quarterly EPS of $1.76, exceeding analysts' expectations, with revenue of $2.46 billion, which is a 4.2% increase year-over-year.
• Currently, a significant 92.80% of Zoetis' stock is owned by institutional investors, indicating strong institutional support and interest in the company.

Nippon Life Global Investors Americas Inc. grew its position in Zoetis Inc. (NYSE:ZTS - Free Report) by 8.0% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 38,740 shares of the company's stock after acquiring an additional 2,880 shares during the quarter. Nippon Life Global Investors Americas Inc.'s holdings in Zoetis were worth $6,379,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the company. Integrated Wealth Concepts LLC boosted its holdings in shares of Zoetis by 13.3% in the first quarter. Integrated Wealth Concepts LLC now owns 7,553 shares of the company's stock valued at $1,244,000 after acquiring an additional 888 shares during the period. Jacobs Levy Equity Management Inc. acquired a new stake in shares of Zoetis in the first quarter valued at approximately $1,916,000. Hancock Whitney Corp boosted its holdings in shares of Zoetis by 4.3% in the first quarter. Hancock Whitney Corp now owns 17,832 shares of the company's stock valued at $2,936,000 after acquiring an additional 738 shares during the period. Edmond DE Rothschild Holding S.A. boosted its holdings in shares of Zoetis by 23.4% in the first quarter. Edmond DE Rothschild Holding S.A. now owns 330,181 shares of the company's stock valued at $54,364,000 after acquiring an additional 62,699 shares during the period. Finally, Eventide Asset Management LLC acquired a new stake in shares of Zoetis in the first quarter valued at approximately $424,000. 92.80% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

ZTS has been the topic of a number of recent research reports. Stifel Nicolaus lowered Zoetis from a "buy" rating to a "hold" rating and dropped their target price for the company from $165.00 to $160.00 in a report on Wednesday, June 18th. Leerink Partnrs downgraded Zoetis from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 17th. Piper Sandler increased their price target on Zoetis from $210.00 to $215.00 and gave the stock an "overweight" rating in a report on Monday, August 11th. Finally, Leerink Partners cut shares of Zoetis from an "outperform" rating to a "market perform" rating and reduced their target price for the stock from $180.00 to $155.00 in a research note on Thursday, July 17th. Four analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $202.43.

Zoetis Price Performance

Zoetis stock traded down $0.05 during midday trading on Friday, reaching $153.15. The company's stock had a trading volume of 1,895,936 shares, compared to its average volume of 2,296,223. Zoetis Inc. has a fifty-two week low of $139.70 and a fifty-two week high of $200.33. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.04 and a current ratio of 1.76. The stock's 50 day simple moving average is $153.16 and its 200 day simple moving average is $157.73. The firm has a market capitalization of $67.87 billion, a PE ratio of 26.36, a P/E/G ratio of 2.46 and a beta of 0.88.

Zoetis (NYSE:ZTS - Get Free Report) last released its earnings results on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, beating analysts' consensus estimates of $1.62 by $0.14. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The company had revenue of $2.46 billion during the quarter, compared to the consensus estimate of $2.41 billion. During the same quarter last year, the company earned $1.56 earnings per share. Zoetis's quarterly revenue was up 4.2% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, equities research analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current year.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.